Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Declines By 21.6%

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 90,900 shares, a decrease of 21.6% from the August 15th total of 115,900 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average daily trading volume, of 496,100 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Tenax Therapeutics in a report on Tuesday, September 10th. They set a “sell” rating on the stock.

Tenax Therapeutics Trading Down 0.8 %

Shares of TENX opened at $3.78 on Tuesday. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20. The company has a 50-day simple moving average of $3.68 and a 200-day simple moving average of $3.66.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. As a group, research analysts anticipate that Tenax Therapeutics will post -6.68 EPS for the current year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.